Patrick Berteloot
Overview
Explore the profile of Patrick Berteloot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
461
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Loverix L, Vergote I, Busschaert P, Vanderstichele A, Venken T, Boeckx B, et al.
Eur J Cancer
. 2023 May;
188:131-139.
PMID: 37245441
Background: The PAOLA-1/ENGOT-ov25 trial showed improved progression-free (PFS) and overall survival (OS) in homologous recombination deficient (HRD) positive patients treated with olaparib, but not when HRD negative (HRD tested with...
2.
Van Cauwenberge J, Borremans K, Van Houdt M, Deblander A, Berteloot P, Han S, et al.
J Natl Cancer Inst
. 2023 May;
115(8):998-999.
PMID: 37216905
No abstract available.
3.
Vanderstichele A, Loverix L, Busschaert P, Van Nieuwenhuysen E, Han S, Concin N, et al.
Gynecol Oncol
. 2022 Feb;
165(1):14-22.
PMID: 35177277
Objective: Comparison of olaparib (OLA) monotherapy versus chemotherapy in patients with platinum-sensitive (PSOC) or platinum-resistant ovarian cancer (PROC). Methods: Patients with measurable disease and ≥ 1 prior line of chemotherapy...
4.
Izci H, Tambuyzer T, Vandeven J, Xicluna J, Wildiers H, Punie K, et al.
Arch Public Health
. 2021 Jun;
79(1):111.
PMID: 34162431
Background: Registration and coding of cause of death is prone to error since determining the exact underlying condition leading directly to death is challenging. In this study, causes of death...
5.
Floris G, Richard F, Hamy A, Jongen L, Wildiers H, Ardui J, et al.
J Natl Cancer Inst
. 2020 Nov;
113(2):146-153.
PMID: 33152071
Background: High levels of stromal tumor-infiltrating lymphocytes (sTIL) are associated with increased pathological complete response (pCR) rate and longer survival after neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) patients. Here,...
6.
Jongen L, Floris G, Wildiers H, Claessens F, Richard F, Laenen A, et al.
Breast Cancer Res Treat
. 2019 May;
176(3):699-708.
PMID: 31106385
Purpose: To assess clinical pathological characteristics and outcome of triple-negative breast cancers (TNBC) by androgen receptor (AR) protein expression. Methods: We retrospectively evaluated AR by immunohistochemistry on core-needle biopsy, (CNB)...
7.
Neven P, Jongen L, Lintermans A, Van Asten K, Blomme C, Lambrechts D, et al.
Clin Cancer Res
. 2018 Feb;
24(10):2312-2318.
PMID: 29459457
Levels of endoxifen, the most active metabolite of tamoxifen, vary by the highly polymorphic cytochrome P450 (CYP) 2D6 enzyme. We prospectively investigated tamoxifen efficacy by serum endoxifen levels and the...
8.
Michielsen K, Dresen R, Vanslembrouck R, De Keyzer F, Amant F, Mussen E, et al.
Eur J Cancer
. 2017 Jul;
83:88-98.
PMID: 28734146
Background: Despite excellent per-lesion performance for peritoneal staging, the additional clinical value of diffusion-weighted magnetic resonance imaging (DWI/MRI) compared to computed tomography (CT) remains to be established in ovarian cancer....
9.
Loyson T, Van Cann T, Schoffski P, Clement P, Bechter O, Spriet I, et al.
Acta Clin Belg
. 2017 Jul;
73(2):100-109.
PMID: 28693379
Objectives: Osteonecrosis of the jaw (ONJ) is a serious adverse event of bone resorption inhibitors (BRIs), such as bisphosphonates and denosumab. Bisphosphonates and denosumab inhibit osteoclast function through different pharmacological...
10.
Amant F, Verheecke M, Wlodarska I, Dehaspe L, Brady P, Brison N, et al.
JAMA Oncol
. 2015 Sep;
1(6):814-9.
PMID: 26355862
Importance: Noninvasive prenatal testing (NIPT) for fetal aneuploidy by scanning cell-free fetal DNA in maternal plasma is rapidly becoming a major prenatal genetic test. Similar to placental DNA, tumor DNA...